-transparent.png){kind=logo}
We treated hyperlipidemia in patients with nephrotic syndrome (NS) using pravastatin for more than one year. There were 7 cases consisting of 3 with minimal change nephrotic syndrome (MCNS), 1 with focal glomerulosclerosis (FGS), 1 with proliferative glomerulonephritis (PGN), 2 with membranous glomerulonephritis (MGN) and 1 of unknown origin. Three cases consisted of frequent relapsers, and 4 were steroid-resistant. Six randomly selected age- and sex-matched nephrotic patients were used as controls. The daily excretion of proteinuria was not decreased after pravastatin treatment, but, the serum albumin rose from 3.1 +/- 1.1 to 3.4 +/- 1.0 mg/dl. The serum total cholesterol level was significantly reduced from 401 +/- 174 mg/dl to 331 +/- 103 mg/dl in spite of an absence of marked change in the control group. However, there were no significant changes in the triglyceride and lipoprotein levels. The atherogenic index was 7.1 +/- 3.7 before and 2.8 +/- 1.7 after pravastatin treatment, respectively. Improvement of renal function defined by delta decrement of renal function per year (0.08 +/- 0.06 vs. 0.12 +/- 0.26) was observed after the discontinuation of pravastatin administration in 3 out of 4 intractable cases. We conclude that pravastatin has a potent effect in reducing the serum level of total cholesterol, but not triglyceride in NS. Furthermore, pravastatin can induce renal dysfunction especially in patients with intractable nephrotic syndrome.
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
July 1993,
American journal of kidney diseases : the official journal of the National Kidney Foundation,
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
April 1992,
Nihon Jinzo Gakkai shi,
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
January 1989,
American journal of nephrology,
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
August 1991,
Ugeskrift for laeger,
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
January 1987,
Nephron,
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
August 1990,
The New England journal of medicine,
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
October 1993,
Pediatric nephrology (Berlin, Germany),
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
December 1988,
American journal of kidney diseases : the official journal of the National Kidney Foundation,
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
July 1985,
Journal of postgraduate medicine,
T Shibasaki, and
H Nakano, and
H Matsuda, and
I Ohno, and
H Matsumoto, and
T Misawa, and
F Ishimoto, and
O Sakai
April 1991,
Kidney international. Supplement,
